To date, our newly designed C-terminal peptide MAP3865c262–275 (DSARVLRDARAVLS) present a 53% amino acid identity with ZnT8326–340 (DSQVVRREIAKALSK) epitope, which was recently reported to be a CD4 (+) T cell target in T1D patients [18]. Here, CD4 is linked to type 1 diabetes mellitus.